A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022

References

• Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016 Jul 11; 113(27–28):470–476.
   PubMedGoogle Scholar
• Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016 Jan;1364(1):32–51.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. CA. Cancer J Clinicians. Internet]. cited 2021 Jan [cited 2022 Jan [cited 2022 Jan 5];71(1):7–33. Available from. 2021. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html
   Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Libby E, Garcia D, Quintana D, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. 2014 Dec;55(12):2850–2857.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol Internet]. 2020 May 1 cited 2022 Jan 5;95(5):548–567. Available from. https://doi.org/10.1002/ajh.25791
   Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. Internet]. 2014 cited 2021 Dec 23;343(6168):305–309. Available from;: https://doi.org/10.1126/science.1244917
   PubMed Web of Science ®Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. Internet]. 2014 cited 2021 Dec 23;343(6168):301–305. Available from;: https://doi.org/10.1126/science.1244851
   PubMed Web of Science ®Google Scholar
• Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature Internet]. 2015 Jul 9 cited 2021 Dec 23;523(7559):183. Available from. https://doi.org/10.1038/nature14610
   Google Scholar
• Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med. 2007 Sep;7(3):83–97.
   PubMedGoogle Scholar
• Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. Internet]. 2012 Mar 1 [cited 2022 Jan 17];18(5):1426–1434.
   PubMedGoogle Scholar
• Pulte ED, Dmytrijuk A, Nie L, et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple Myeloma. Oncologist. 2018 Jun;23(6):734–739.
   PubMed Web of Science ®Google Scholar
• Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. Internet]. 1988 cited 2021 Dec 27;57(1):94–99. Available from;: https://pubmed.ncbi.nlm.nih.gov/3279997/
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000 Nov;11(11):1427–1436.
   PubMed Web of Science ®Google Scholar
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001 Jun;113(4):1020–1034.
   PubMed Web of Science ®Google Scholar
• Wisløff F, Hjorth M, Kaasa S, et al. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. the nordic myeloma study group. Br J Haematol. 1996 Aug;94(2):324–332.
   PubMedGoogle Scholar
• Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002 May;99(9):3163–3168.
   PubMed Web of Science ®Google Scholar
• Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol. 2007 Jan;136(2):203–211.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Dimopoulos M, et al. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol. 2000 Nov;65(3):204–209.
   PubMedGoogle Scholar
• Bird JM, Owen RG, D’Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. Internet]. 2011 Jul 1 cited 2021 Dec 31;154(1):32–75. Available from:, https://doi.org/10.1111/j.1365-2141.2011.08573.x
   Google Scholar
• Ludwig H, Durie BGM, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar;119(13):3003–3015.
   PubMed Web of Science ®Google Scholar
• Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs Internet]. 2017 Apr 1 cited 2021 Dec 31;77(5):505. Available from. /pmc/articles/PMC5705939/
   PubMedGoogle Scholar
• Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 5 119(1):7–15.
   PubMedGoogle Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol. 2004 Aug 1; 15(8):1151–1160.
   PubMedGoogle Scholar
• Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the national cancer institute of canada clinicals trials group myeloma 10 trial. Blood. 2013 Feb;121(9):1517–1523.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol Internet]. 2012 Aug 20 cited 2021 Dec 31;30(24):2946–2955. Available from. https://pubmed.ncbi.nlm.nih.gov/22802322/
   PubMedGoogle Scholar
• Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol. Internet]. 2005 Oct cited 2021 Dec 31;1(5):575–583. Available from. https://pubmed.ncbi.nlm.nih.gov/16556034/
   PubMedGoogle Scholar
• Alegre A, Vicuña I, Aguado B. Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol. 2011;6:1–10. December/06.
   PubMedGoogle Scholar
• Chen N, Zhou S, Palmisano M. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clin Pharmacokinet. Internet]. 2017 Feb 1 cited 2022 Jan 5;56(2):139–152. Available from:, https://pubmed.ncbi.nlm.nih.gov/27351179/
   PubMedGoogle Scholar
• Shank BR, Brown VT, Schwartz RN. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment. J Oncol Pharm Pract. 2015;21(1):36–51.
   PubMedGoogle Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. N Engl J Med. 2012 May 9 366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol Internet]. 2017 Sep 1 cited 2021 Dec 31;4(9):e431–42. Available from. https://pubmed.ncbi.nlm.nih.gov/28826616/
   PubMedGoogle Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide Maintenance after Stem-Cell transplantation for multiple myeloma. N Engl J Med. 2012 May 9 366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. Internet]. 2014 Sep 4 cited 2021 Dec 27;371(10):895–905. Available from:, https://pubmed.ncbi.nlm.nih.gov/25184862/
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J clin oncol. 2017;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. Internet]. 2019 Jan 1 cited 2021 Dec 31;20(1):57–73. Available from:, https://pubmed.ncbi.nlm.nih.gov/30559051/
   PubMedGoogle Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med Internet]. 2012 May 10 cited 2022 Feb 27;366(19):1759–1769. Available from. https://pubmed.ncbi.nlm.nih.gov/22571200/
   PubMedGoogle Scholar
• Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood Internet]. 2021 Jun 3 cited 2021 Dec 27;137(22):3027–3036. Available from. https://pubmed.ncbi.nlm.nih.gov/33739404/
   PubMedGoogle Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.2019 Jan 1 20(1):57–73.
   PubMedGoogle Scholar
• Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. Internet]. 2011 Nov cited 2022 Jan 5;10(11):2034. Available from. /pmc/articles/PMC5527560/
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014 Mar;28(3):690–693.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2020 December [//22];8(1):e45–54.
   PubMedGoogle Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19cited 2021 Dec 27 39310168: 253–264, Available fromhttps://pubmed.ncbi.nlm.nih.gov/30545780/
   PubMedGoogle Scholar
• Patel KK, Shah JJ, Feng L, et al. Update on a phase ii study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. Blood. [2017 Dec 7];130(Supplement 1):437.
   Google Scholar
• Rosinol L, Oriol A, Ríos Tamayo R, et al. Ixazomib plus lenalidomide/dexamethasone (ird) versus lenalidomide /dexamethasone (rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: results of the Spanish gem2014main trial. Blood. 2021 Nov 23 138(Supplement 1):466.
   Google Scholar
• Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood Internet]. 2021 Jul 1 cited 2021 Dec 27;137(26):3616–3628. Available from. https://pubmed.ncbi.nlm.nih.gov/33763699/
   PubMedGoogle Scholar
• Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol Internet]. 2020 Dec 1 cited 2022 Apr 9;38(34):4030–4041. Available from. https://pubmed.ncbi.nlm.nih.gov/33021870/
   PubMedGoogle Scholar
• Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol Internet]. 2021 Dec 1 cited 2021 Dec 27;22(12):1705–1720. Available from. https://pubmed.ncbi.nlm.nih.gov/34774221/
   PubMedGoogle Scholar
• Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. Internet]. 2021 Oct 1 cited 2022 Apr 9;22(10):1378–1390. Available from:, http://www.thelancet.com/article/S1470204521004289/fulltext
   PubMedGoogle Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug;136(8):936–945.
   PubMed Web of Science ®Google Scholar
• Laubach J. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (rvd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (ndmm): updated analysis of griffin after 24 months of maintenance. : ASH; 2021 Abstract 79 .
   Google Scholar
• Goldschmidt H. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. ASH. 2021 Abstract 463 .
   Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol Internet]. 2021 Nov 1 cited 2022 Feb 13;22(11):1582–1596. Available from. https://pubmed.ncbi.nlm.nih.gov/34655533/
   PubMedGoogle Scholar
• Thomas SK, Shah JJ, Morin A, et al. Update of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (pts) with multiple myeloma (MM). Blood. 2020;136(Supplement 1):46–47.
   Google Scholar
• Goldschmidt H. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: results from the Randomized Phase III GMMG-HD6 Trial. ASH. 2021 Abstract 486 .
   Google Scholar
• Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. Internet]. 2019 cited 2022 Jan 17;37(7):589–597. Available from;: https://pubmed.ncbi.nlm.nih.gov/30653422/
   PubMed Web of Science ®Google Scholar
• Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) J Clin Oncol . https://doi.org/10.1200/JCO20203815suppl8506 2020May25. 3815.
   Google Scholar
• Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol Internet]. 2015 Oct 20 cited 2021 Dec 27;33(30):3459–3466. Available from. https://pubmed.ncbi.nlm.nih.gov/26282661/
   PubMedGoogle Scholar
• D’Agostino M, de Paoli L, Conticello C, et al. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: a pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol. Internet]. 2018 Dec 1 cited 2021 Dec 27;132:9–16. Available fromhttps://pubmed.ncbi.nlm.nih.gov/30447931/
   PubMedGoogle Scholar
• Amsler IG, Jeker B, Mansouri Taleghani B, et al. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. Leuk Lymphoma. Internet]. 2019 Jan 28 cited 2021 Dec 27;60(2):511–514. Available from.: https://pubmed.ncbi.nlm.nih.gov/30616438/
   PubMedGoogle Scholar
• Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. Internet]. 2020 Jul 1 cited 2021 Dec 27;34(7):1853–1865. Available from:, https://pubmed.ncbi.nlm.nih.gov/32034285/
   PubMedGoogle Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol Internet]. 2017 Jan 1 cited 2021 Dec 27;3(1):28–35. Available from. https://pubmed.ncbi.nlm.nih.gov/27632282/
   PubMed Web of Science ®Google Scholar
• Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. Internet]. 2020 Jun 1 cited 2022 Jan 5;7(6):e456–68. Available from:, https://pubmed.ncbi.nlm.nih.gov/32359506/
   PubMedGoogle Scholar
• Rde T, Pawlyn C, Cairns D, et al. OAB-015: minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk. Clin Lymphoma Myeloma Leukemia. 2021 Oct 1;21:S10.
   Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease Response-Adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol [Internet]. 2021 Dec 13 cited 2021 Dec 27]; Available from 2021 Dec 27: https://pubmed.ncbi.nlm.nih.gov/34898239/
   Google Scholar
• Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol Internet]. 2021 Jun 1 cited 2022 Jan 17;7(6):862–868. Available from. https://pubmed.ncbi.nlm.nih.gov/33856405/
   PubMedGoogle Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase iii myeloma XI study. Blood. 2016 Jan 1 128(22):1143.
   Google Scholar
• Jackson G, Davies FE, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial. Washington DC: American Society of Hematology; 2017.
   Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple Myeloma. N Engl J Med Internet]. 2014 Sep 4 cited 2021 Dec 31;371(10):895–905. Available from. https://doi.org/10.1056/nejmoa1402888
   Google Scholar
• McCarthy PL, Richardson P, Suman V, et al. Survival analysis from the calgb study of lenalidomide maintenance therapy in newly diagnosed multiple myeloma post-autologous stem cell transplantation adjusted for crossover (Alliance 100104). Blood. 2018 Nov 29 132(Supplement 1):4737.
   Google Scholar
• Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 Feb;10(2):17.
   PubMed Web of Science ®Google Scholar
• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017 Apr;129(17):2359–2367.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai E, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020 Jul 1 34(7):1–13.
   PubMedGoogle Scholar
• Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Vol. 124. United States: Blood.; 2014. p. 2467–2468.
   Google Scholar
• Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma : results from the phase III GMMG-MM5 trial. Leukemia. 2020 34 (7) p.1853–1865 .
   PubMedGoogle Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1617–1629.
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007 Dec;47(12):1466–1475.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou S, Palmisano M. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clin Pharmacokinet. 2017 Feb;56(2):139–152.
   PubMed Web of Science ®Google Scholar
• Jones JR, Pawlyn C, Jackson GH. Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert Opin Drug Saf. 2021 Oct;20(10):1137–1145.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Delforge M, Song K, et al. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Leuk Lymphoma. 2018 Feb;59(2):398–405.
   PubMed Web of Science ®Google Scholar
• Delforge M, Minuk L, Eisenmann J-C, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015 March [//13];100(6):826–833.
   PubMed Web of Science ®Google Scholar
• Boquoi A, Giagounidis A, Goldschmidt H, et al. Similar quality of life with 5mg versus 25mg lenalidomide maintenance after first-line high-dose therapy and autologous blood stem cell transplantation for multiple myeloma: results of the lenamain trial. Blood. 2018 Nov 29 132(Supplement 1):2003.
   Google Scholar
• Abonour R, Wagner L, Durie BGM, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018 Dec;97(12):2425–2436.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Hillengass J, McCarthy PL. Next-generation drugs targeting the cereblon ubiquitin ligase. J clin oncol. 2018 Jul 10; 36(20):2101–2104.
   PubMedGoogle Scholar
• Lonial S, van de DNWCJ, Popat R, et al. First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) ASCO . https://doi.org/10.1200/JCO20193715.l8006 2019May26. 3715.
   Google Scholar
• Merz AMA, Merz M, Zhang Y, et al. Serological response to vaccination after autologous transplantation for multiple myeloma is associated with improved progression-free and overall survival. Transplant Cell Ther 2021 Mar 1 Mar 1;27(3):245.e1–245.e8. Available from. https://doi.org/10.1016/j.jtct.2020.11.009
   Google Scholar